Liquid Biopsy 2026: Galleri & Shield Detect Cancer From a Single Blood Draw
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-06-05 · 8 min read
Multi-cancer early detection (MCED) blood tests now screen for 50+ cancers with 92% specificity. Who should get tested and how to interpret results.
One Tube, 50+ Cancers
Liquid biopsies sequence circulating tumor DNA (ctDNA) from a blood draw. The 2026 PATHFINDER-2 study validated GRAIL Galleri across 175,000 adults.
Leading Tests
- Galleri (GRAIL): 50+ cancers, 99.5% specificity, $949 cash
- Shield (Guardant): FDA-approved CRC screen, Medicare covered
- Cologuard Plus: stool DNA + methylation, age 45+
- Reveal (Natera): post-op recurrence monitoring
Who Should Consider MCED
- Adults age 50+ (Galleri label)
- Strong family history of cancer
- Heavy smoking history (lung-focused panels)
- BRCA1/2 carriers as adjunct surveillance
Limitations
- Not a replacement for mammograms, colonoscopy, low-dose CT
- False positives ~0.5% — confirmatory imaging required
- Sensitivity lower for stage I prostate and breast cancer
Insurance (2026)
Medicare now covers Shield for CRC screening. Commercial coverage of Galleri remains spotty — most patients pay cash.